Responses
Regular and Young Investigator Award Abstracts
Clinical Trials In Progress
479 AGEN1181, an Fc-enhanced anti-CTLA-4 antibody, alone and in combination with balstilimab (anti-PD-1) in patients with advanced solid tumors: Initial phase I results
Compose a Response to This Article
Other responses
No responses have been published for this article.